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Transitioning From a Focus on Individual Lesions to
Atherosclerotic Disease Burden for Coronary Artery Disease
Risk AssessmentArmin Arbab-Zadeh, MD, PHD,* Valentin Fuster, MD, PHDyABSTRACTFro
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MaThe cardiovascular science community has pursued the quest to identify vulnerable atherosclerotic plaque in patients for
decades, hoping to prevent acute coronary events. However, despite major advancements in imaging technology that allow
visualization of rupture-prone plaques, clinical studies have not demonstrated improved risk prediction compared with
traditional approaches. Considering the complex relationship between plaque rupture and acute coronary event risk sug-
gested bypathology studies and conﬁrmedby clinical investigations, these results are not surprising. This review summarizes
the evidence supporting a multifaceted hypothesis of the natural history of atherosclerotic plaque rupture. Managing pa-
tients at risk of acute coronary eventsmandates a greater focus on the atherosclerotic disease burden rather thanon features
of individual plaques. (J Am Coll Cardiol 2015;65:846–55) © 2015 by the American College of Cardiology Foundation.C ardiovascular atherosclerotic disease is theleading cause of death in Western industrial-ized nations and in developing countries (1).
Strategies to prevent acute coronary events and their
sequelae are among our most important public health
priorities (2). Identifying patients at increased risk
of acute coronary events who may beneﬁt from
intensiﬁed preventative measures is a major,
ongoing challenge (2). Numerous factors (e.g., dysli-
pidemia, diabetes, and others), are associated with
increased rates of adverse events; however, their
hazard rates are too small for accurate individual
risk assessments (3). The DIAD (Detection of Is-
chemia in Asymptomatic Diabetics) trial revealed
that after 4.8 years of follow-up, 97% of asymptom-
atic patients with diabetes mellitus remained free
of myocardial infarction and cardiac death (4). Even
when combined as comprehensive risk scores (e.g.,
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The mechanisms leading to adverse events from
atherosclerotic disease are clearly more complex than
initially assumed, explaining our difﬁculties in accu-
rately predicting events in individuals (7,8). In addi-
tion to the presence, extent, and metabolic activity of
atherosclerotic disease, individual adaptations and
responses to thrombogenic stimulation from altered
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FIGURE 1 Risk of MI or Death Associated With
Individual Plaques in the PROSPECT Study
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Maximum annualized risks (percent) of myocardial infarction (MI)
or cardiovascular (CV) death associated with individual coronary
atherosclerotic plaques identiﬁed at baseline by intravascular
ultrasound-virtual histology in the PROSPECT (Providing
Regional Observations to Study Predictors of Events in the
Coronary Tree) study are shown (18). The rates are based on the
occurrence of 6 events (6 myocardial infarctions and no deaths)
after 3.4 years of follow-up among 1,005 coronary arterial sites
with pathological intimal thickening and 595 thin-cap atheromas
(TCFAs), assuming all events were caused by the respective
plaque type, thus representing the worst-case scenario.
Considering equal risk among the 3,160 plaques detected at
baseline (best-case scenario), the event rate associated with each
plaque would be only 0.06% per year. The risk of MI or death
associated with individual TCFAs or vulnerable plaques is much
smaller than what is conventionally considered high risk, even
when maximal risk is assumed.
AB BR E V I A T I O N S
AND ACRONYM S
IVUS = intravascular
ultrasound
TCFA = thin-cap ﬁbroatheroma
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847complexity of the processes leading to risk and lacks
supporting evidence. In this review, we summarize
the shift from conceptualizing acute coronary event
risk as a simple cause-and-effect principle centered
on high-risk plaques to a complex model involving
numerous factors.
THE “VULNERABLE PLAQUE” CONCEPT
Pathology studies have demonstrated the common
association of acute myocardial infarction with the
rupture or erosion of a coronary atherosclerotic pla-
que (13,14), most frequently a thin-cap ﬁbroatheroma
(TCFA), characterized by a large lipid or necrotic core
separated from the coronary arterial lumen by a thin
membrane cap (15). Thus, the identiﬁcation of TCFAs
in humans was assumed to signify a high risk of
ensuing acute coronary events, which then might
necessitate directed treatment or speciﬁc preventa-
tive measures (16). Accordingly, enormous efforts
have been undertaken to enable the identiﬁcation of
TCFAs and other high-risk plaque features in humans.
The search term vulnerable plaque ﬁnds more than
400 current National Institutes of Health research
awards totaling more than $150 million per year (17)
and almost 2,000 research papers in the National
Library of Medicine database. Although not all of
these efforts aim to identify “vulnerable plaques,”
this topic is clearly central to many investigations
involving large amounts of research dollars. Industry
has also been keenly interested in developing
technologies for the visualization of “vulnerable
plaques,” with progression of several catheter-
based inventions, notably intravascular ultrasound
(IVUS)-virtual histology, thermography, infrared
spectroscopy, palpography, and optical coherence
tomography (OCT) to preclinical or clinical stages
(12,18).
LIMITATIONS OF STUDIES SUPPORTING
THE HIGH-RISK ATHEROSCLEROTIC
PLAQUE CONCEPT
A number of clinical investigations used various im-
aging tools to identify high-risk atherosclerotic pla-
que features in order to predict an increased risk of
adverse events. In one large, prospective clinical
study, PROSPECT (Providing Regional Observations
to Study Predictors of Events in the Coronary Tree),
rates of adverse cardiac events according to types of
coronary atherosclerotic plaque were investigated in
more than 600 high-risk patients studied with IVUS-
virtual histology (19). Although 596 TCFAs were
identiﬁed, only repeat hospitalization for chest pain
was associated with events. This was expected, giventhe typically larger luminal encroachment of
TCFAs compared with pathological intimal
thickening (the prevalent type of lesion in the
study). However, the risk of myocardial
infarction or sudden cardiac death related to
these lesions was very low (Figure 1). A
similar study using IVUS-virtual histology (VIVA [VH-
IVUS in Vulnerable Atherosclerosis]) reported nearly
identical ﬁndings (20). Studies using OCT revealed
greatly detailed plaque characteristics in patients
with acute coronary syndromes and other at-risk
populations (21). Similar to the information provided
by IVUS, studies using OCT suggest that a larger
lesion plaque burden might indicate an increased risk
of acute coronary events (22). Noninvasive imaging
studies of the coronary arteries using computed
tomographic angiography reported increased rates of
acute coronary syndromes in patients with low-
attenuation plaques (presumably high in lipid con-
tent) with external remodeling compared with those
without such plaques (23–25). Puchner et al. (26)
recently reported independent prediction of acute
TABLE 1 Prevalence of Subclinical Coronary Atherosclerotic Plaque Ruptures (Percent)
in Patients With Stable Coronary Heart Disease or Healthy Controls and in Patients With
Acute Coronary Syndromes
First Author (Ref. #)
Mode of
Assessment
Number of
Stable CHD
Patients or
Controls*
Nonculprit
Plaque
Ruptures (%)
Number
of ACS
Patients
Nonculprit
Plaque
Ruptures (%)
Arbustini et al. (30) Pathology 77* 17 106 58
Cheruvu et al. (38) Pathology 13* 31 33 45
Rioufol et al. (41) IVUS — — 24 79
Kotani et al. (37) IVUS 48 6 38 11
Schoenhagen et al. (36) IVUS 92 4 105 19
Hong et al. (35) IVUS 113 5 122 17
Tanaka et al. (29) IVUS — — 45 24
Takano et al. (34) Angioscopy — — 327 9
Tanaka et al. (33) OCT — — 45 24
Tian et al. (22) OCT — — 82 10
Shimamura et al. (32) OCT 191 17 — —
Total 444 927
Median 11.5 21.5
Multiple asymptomatic plaque ruptures are more frequently found in patients with ACS than in those with stable
CHD or healthy controls, indicating the systemic inﬂammatory state in the coronary arteries with acute events.
*Healthy controls.
ACS¼ acute coronary syndrome; CHD¼ coronary heart disease; IVUS¼ intravascular ultrasound; OCT¼ optical
coherence tomography.
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848coronary syndrome using computed tomography to
identify similar high-risk characteristics in patients
presenting with acute chest pain. Finally, plaque
hemorrhage, assessed by magnetic resonance imag-
ing, has been implicated in poor outcomes in patients
with cerebrovascular disease (27,28). However, all of
these studies claiming independent risk prediction of
certain plaque features share the fundamental limi-
tation that the atherosclerotic disease burden was not
considered as a potential confounder. These “high-
risk” features are conceivably mere markers of more
extensive and/or active atherosclerotic disease
compared with the control group. Given the over-
whelming evidence for disease burden as a powerful
predictor of outcome, any additional risk features
should be assessed against it before we assume in-
dependent risk prediction. Therefore, despite prom-
ising results from a number of clinical studies, there is
no conclusive evidence for truly independent risk
prediction associated with high-risk plaque features.
High-risk features may still be valuable as markers for
disease burden or activity; however, such value has
not been established.
EVIDENCE DIMINISHING THE SIGNIFICANCE
OF IDENTIFYING “HIGH-RISK” PLAQUES
Despite our ability to identify atherosclerotic lesions
that exhibit vulnerable characteristics using various
imaging tools, clinical studies have failed to demon-
strate meaningful clinical utility for plaque imaging.These negative results are explained by the numerous
pathological and clinical investigations demon-
strating that many (if not most) plaques rupture
without clinical syndromes (22,29–38). The percent of
patients with subclinical plaque ruptures varies with
their risk proﬁle and the sensitivity of assessment
methods, ranging from 4% to 79% (Table 1). Plaque
rupture and its healing are frequently clinically silent
but lead to progressive lumen obstruction (39,40). In
lesions with advanced lumen narrowing (>50% ste-
nosis), histopathology almost invariably reveals 1 or
more healed subclinical plaque ruptures (39–41).
Because healed plaque ruptures can be detected by
pathology or imaging only within a certain time frame
after the initial plaque disruption, the true rate of
asymptomatic plaque ruptures is probably under-
estimated (40). In most patients with advanced
atheroma, plaque rupture and subsequent healing
have already occurred (40). Pathology studies show
that approximately 10% of the subclinical United
States adult population exhibits advanced coronary
atheroma (42), so it is reasonable to assume that
many millions of persons unknowingly experience
plaque ruptures each year.
Several longitudinal imaging studies in humans
have demonstrated that plaque morphology changes
over a few months, gaining or losing “vulnerable”
characteristics (43–45). Using IVUS, Kubo et al. (43)
found that 75% of TCFAs transition to thick-cap
ﬁbroatheromas or ﬁbrotic plaques within a 12-month
interval, presumably secondary to rupture and heal-
ing (Figure 2). None of these patients experienced
events during this period, providing further evidence
of frequent subclinical plaque alterations. A recent
study used OCT to conﬁrm the dynamic nature of
coronary atherosclerotic disease, demonstrating that
TCFAs in various stages of development are highly
prevalent in patients with coronary atherosclerotic
disease (46). In patients with acute coronary syn-
dromes, plaque ruptures are frequently found apart
from the culprit lesions, indicating that vulnerability
is disseminated throughout the coronary tree (41).
This suggests that detection of a state of vulnerability
in a patient (e.g., widespread inﬂammation) is more
important than detection of individual sites of
vulnerability. The emerging picture of acute coronary
event pathophysiology suggests a widespread, sys-
temic condition with great unpredictability as to
which particular lesion will be associated with clini-
cally signiﬁcant vascular thrombosis (47). Although
plaque ruptures and erosions are indeed respon-
sible for most culprit lesions in patients with acute
events, because the frequency of subclinical plaque
ruptures is vastly underestimated, the assumption
FIGURE 2 Changes in TCFAs During 12 Months of Follow-Up
Thin Cap Fibroatheromas
Thick Cap Fibroatheromas
Thin Cap Fibroatheromas
Fibrotic Plaques
Changes in thin-cap ﬁbroatheromas (TCFA) observed with intravascular ultrasound-virtual
histology 12 months after baseline imaging. Of 20 TCFAs, only 5 remained unchanged,
while 15 (75%) lost vulnerable characteristics and revealed thickening of the ﬁbrous cap or
transformed into ﬁbrous plaques. The data (Kubo et al. [43]) demonstrate high metabolic
activity in atherosclerotic lesions and the short-lived nature of vulnerable plaque char-
acteristics. None of the 99 patients experienced any events during follow-up; thus, many
of the observed changes were likely the result of subclinical plaque ruptures.
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849that identifying lesions prone to rupture will prevent
acute coronary events was unrealistic. Of the many
plaque ruptures occurring in patients with athero-
sclerotic disease, very few will trigger symptomatic
events, rendering it exceedingly difﬁcult to predict
adverse outcomes associated with particular lesions.
Identifying a single TCFA or other “high-risk plaque,”
without considering other clinical or imaging char-
acteristics, is unlikely to be of incremental beneﬁt for
risk prediction over established factors (e.g., the
extent and distribution of atherosclerotic plaque
burden), because of the low risk associated with a
given individual plaque and the temporal relation-
ship of its vulnerable characteristics.
CURRENT PARADIGM OF ACUTE CORONARY
EVENT PATHOPHYSIOLOGY
Over the past few decades, clinical and laboratory
investigations have led to a more complex concept of
the pathophysiology of acute coronary events,
involving numerous processes, many with poorly
understood interactions (7,8). Although the occur-
rence of acute coronary events typically requires
alterations of coronary atherosclerotic plaques
(rupture or erosion), a thrombosis-promoting milieu
is necessary to allow a clinically signiﬁcant decrease
in coronary blood ﬂow and associated myocardial
ischemia (7,9). Such a setting appears to result from
an unfortunate constellation of prothrombotic fea-
tures, for example, in patients with increased in-
ﬂammatory activity and systemic or local suppression
of ﬁbrinolytic performance, an extraordinarily large
stimulus for thrombosis, vasoconstriction, and/or
others (7). The respective contributions of these fac-
tors (some hereditary, some environmental) and
their temporal relationships necessary to trigger
clinically meaningful vascular thrombosis are un-
known. Factors favoring thrombosis need to be
collectively sufﬁcient to tilt the scale away from
localized thrombus and toward extensive vascular
thrombosis (Central Illustration). Because numerous
factors inﬂuence the performance of the coagulation
system at any given point in time, acute coronary
events may arise as result of a “perfect storm” sce-
nario, in which plaque disruption occurs in a
speciﬁc, thrombosis-promoting setting (7). The risk of
an acute coronary event equals the probability of
plaque rupture or erosion coinciding with vascular
thrombosis-promoting conditions that cannot
contain the thrombus in the vascular wall. Frequent
plaque ruptures, as with a large, metabolically
active atherosclerotic disease burden, increase
the chance that a plaque rupture coincides witha thrombosis-conducive setting. Accordingly, the
strongest predictors of adverse events are the magni-
tude and activity of the coronary atherosclerotic
plaque burden and the number of risk factors for a
prothrombotic milieu, a concept supported by many
clinical studies and epidemiologic data (3,5,48–50).
LESION FOCUSED VERSUS DISEASE
BURDEN FOCUSED RISK ASSESSMENT
AND MANAGEMENT
Numerous clinical studies using conventional inva-
sive coronary angiography, IVUS, and cardiac com-
puted tomography (8,48,51) have conﬁrmed the
strong relationship between atherosclerotic disease
burden and risk for adverse events. Despite capturing
only calciﬁed atherosclerotic disease, when compared
directly, coronary calcium scoring was equivalent to
traditional stenosis assessment for predicting mor-
tality and myocardial infarction in asymptomatic pa-
tients (52). Using a comprehensive imaging approach
in several vascular beds, the BioImage study recently
revealed a high prevalence of atherosclerotic disease
in patients categorized as high risk for cardiovascular
events on the basis of clinical predictors (53). Halting
coronary atherosclerotic disease progression and/or
altering the vascular thrombosis-promoting milieu
via platelet inhibition and risk factor interdiction are
approaches proved to lower myocardial infarction
and death rates (54–56). Conversely, meta-analyses
have not demonstrated reduced rates of myocardial
CENTRAL ILLUSTRATION Fate of Ruptured Coronary Atherosclerotic Plaques According to Thrombotic Milieu
The hypothesized interplay of prothrombotic and thrombosis resisting and containing factors that presumably determine the outcome of a ruptured coronary
atherosclerotic plaque is shown. (A) In the most common scenario, small thrombus formation associated with plaque rupture is contained and vascular occlusive
thrombus is inhibited. (B) In the less common scenario of several prothrombotic factors coinciding (e.g., inﬂammatory state, large lesion plaque burden, vasocon-
striction, circadian rheological changes), local thrombosis associated with plaque rupture cannot be contained, and clinically signiﬁcant vascular thrombosis occurs,
triggering an acute coronary syndrome (ACS). The constellation of factors leading to these different outcomes is unknown.
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FIGURE 3 Risk Due to Nonobstructive Versus
Obstructive Coronary Artery Disease
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Annualized risk (percent) of myocardial infarction (MI) or car-
diovascular (CV) death in 3,242 patients followed for a median of
3.6 years after baseline computed tomographic coronary angi-
ography, according to the extent and severity of coronary artery
disease (70). Risk is low in patients with nonobstructive disease
(<50% stenosis) involving 4 or fewer coronary artery segments
(limited disease). Conversely, risk is similarly high in patients with
nonobstructive disease if more than 4 segments are affected
(extensive disease) compared with patients with obstructive
disease ($50% stenosis). Modiﬁed with permission from
Bittencourt et al. (70).
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851infarction or death with lesion-based treatment
(i.e., percutaneous coronary intervention) compared
with medical therapy in patients with stable coronary
artery disease (57,58). Contradicting some earlier
reports (59–62), no beneﬁt was shown, even when
selecting patients with hemodynamically signiﬁcant
stenoses. These results conﬁrm that risk is most
strongly conveyed by the extent of coronary artery
disease, but not necessarily by individual lesions,
even when highly obstructive. This supports the
controversial idea that severe coronary artery stenoses
confer no greater risk of triggering acute coronary
events than mild lesions (63). Earlier angiographic
studies suggested that most myocardial infarctions
arise from mild coronary artery stenoses (64,65), but
recent data question this paradigm (66,67). Thrombus
material accumulates over several days after a plaque
disruption, which may not allow lesion size and a
partly organized thrombus to be accurately distin-
guished (66). Pathology studies in patients who died
suddenly found culprit lesions to have an average
diameter stenosis of approximately 50%, with no clear
relationship between stenosis severity and risk of
death (68,69). Conversely, acute coronary death rarely
results from lesions with <30% luminal stenosis
(66,69). Thus, a certain local plaque volume appears
necessary to trigger vascular thrombosis. However,
given the lack of beneﬁt with coronary stenting, aswell
as the large number of obstructive lesions found by
imaging and autopsy in patients without symptoms of
acute coronary events, stenosis severity is unlikely to
substantially alter such risk beyond a particular
threshold. Patients with high-grade coronary artery
stenoses may conceivably carry an increased risk of
myocardial infarction and death because these lesions
are markers for advanced atherosclerotic disease in
the coronary tree (7). Consistent with this notion,
nonobstructive and obstructive coronary artery dis-
ease are associated with similar risks of myocardial
infarction and death if the former affects a larger
number of coronary arterial segments (Figure 3) (70).
Overall, strong evidence supports addressing the
extent and activity of the atherosclerotic burden and
thrombosis-promoting risk factors for improved pa-
tient outcomes, but there is no conclusive evidence
of incremental risk reduction with lesion-speciﬁc
treatment.
AREAS OF UNCERTAINTY:
INFLUENCE OF STUDY POPULATION
The atherosclerotic disease burden is a powerful
predictor of outcomes for patients without history
of coronary artery disease, facilitated by the ease ofcoronary calcium scanning, which approximates the
total coronary atherosclerotic disease volume (71).
However, it is infrequently performed in patients
with established coronary artery disease; thus, in this
population, plaque burden data are more limited.
Risk characteristics and the need for assessment may
conceivably differ in patients with established coro-
nary artery disease compared with those with history
of acute coronary syndromes. Aside from calcium
scanning, plaque burden assessment is technically
difﬁcult, and most available data were derived from
IVUS imaging. Atherosclerotic plaque burden assess-
ment using computed tomographic angiography has
recently become feasible, but long-term outcome
data are not yet available (72). Aggregate data from
IVUS-derived plaque burden assessment reveal strong
predictive power for outcomes in patients with
established coronary artery disease (73). Conventional
angiographic data for atherosclerotic disease burden
are similarly predictive of patient outcomes and su-
perior to myocardial ischemia testing in an analysis
of the COURAGE (Clinical Outcomes Utilizing Revas-
cularization and Aggressive Drug Evaluation) study
(74). Thus, the risk associated with plaque burden
applies to both asymptomatic patients without prior
cardiac events and those with established, stable
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852coronary artery disease. Whether lesion-based treat-
ment (aside from the culprit lesion) is beneﬁcial in
patients with acute coronary syndrome is unclear. Two
recent small clinical studies suggested reduced rates of
myocardial infarction and death after percutaneous
coronary intervention of nonculprit lesions in pa-
tients with ST-segment elevation myocardial in-
farctions (75,76), in stark contrast to large, aggregate
data suggesting the opposite (77). In addition to con-
cerns about the effect of chance, given the small
numbers of events in these 2 studies, the contribu-
tions of event allocation (e.g., differentiating sponta-
neous and periprocedural events) and varying levels
of expertise at the study centers to these results
remain unclear. PROSPECT, conducted in patients
with acute coronary syndromes, found low risk of
myocardial infarction and death associated with non-
culprit lesions within 3 years of follow-up (19). A large
clinical study, COMPLETE (Complete vs Culprit-Only
Revascularization to Treat Multi-Vessel Disease After
Primary PCI for STEMI), is underway to conclusively
address the question of beneﬁt of stenting non-
culprit lesions in patients with ST-segment elevation
myocardial infarction (78).
IS THERE A ROLE FOR
INDIVIDUAL PLAQUE IMAGING?
Coronary artery imaging has provided insights into
numerous lesion characteristics, but we have yet to
identify which are useful for guiding management.
Changing patterns of lesion characteristics, resulting
from widespread use of lipid-modifying medications,
pose an additional challenge (79). There are prom-
ising data for characterizing coronary arterial lesions
before percutaneous interventions (80,81). Heavily
calciﬁed lesions adversely affect the outcome of cor-
onary artery revascularization, and imaging data may
help weigh treatment options (82,83). Similarly,
knowledge of complex bifurcation lesions before
cardiac catheterization may avoid high-risk in-
terventions (80,81). Plaque imaging also may eluci-
date the effects of drugs on atherosclerotic disease
(84). Individual plaque features may have particular
signiﬁcance in speciﬁc settings; for example, TCFAs
may have different implications in patients with or
without known susceptibility to vascular thrombosis.
Thus, integration of lesion characteristics with
risk factors may be valuable. Currently unknown
features of atherosclerotic plaque may conceivably
independently herald poor outcome. Advanced im-
aging techniques (e.g., molecular imaging) may
elucidate such features and allow further in-
sights into mechanisms of acute coronary eventpathophysiology (85). To determine truly indepen-
dent risk prediction, any plaque assessment should
be measured against the predictive power of athero-
sclerotic burden and its metabolic activity.
IMPLICATIONS FOR
FUTURE INVESTIGATIONS
Although general morphologic patterns of atheroscle-
rotic disease inﬂuence the probability of acute coro-
nary syndromes, they are clearly modiﬁed by
individual characteristics. Pathology and IVUS studies
show that most United States adults older than 50
years have evidence of coronary atherosclerotic dis-
ease, but only a minority will experience acute events
(42,86). Furthermore, the patterns and morphologic
features of atherosclerotic disease appear similar
among populations, suggesting that the patient’s
response to a thrombogenic trigger is critical for
determining the probability of events. Traditional risk
factors for coronary artery disease (e.g., diabetes,
smoking, dyslipidemia) and genetic predisposition
modify such responses. Several mutations are associ-
ated with increased event hazard, and individualized
risk characterization may soon be available (87–89).
We need a better understanding of which combination
of imaging information and risk factors yields the most
accurate individual risk prediction. Research is needed to
investigate mechanisms inﬂuencing the coagulation
system’s response to various internal and external mod-
iﬁers, both locally and systemically. Speciﬁcally, we need
to understand and potentially to predict the response of
the coagulation system to stimuli occurring with athero-
sclerotic plaque alterations. Variability in the coagulation
system’s performance depends on numerous hormonal,
dietary, and environmental inﬂuences, hampering our
ability to predict its function at a given time, for example,
when plaque ruptures (90–92). Thus, we must strive
for comprehensive risk assessment that integrates
speciﬁc information on the atherosclerotic plaque burden
and systemic factors that increase the risk for disease
activity and vascular thrombosis and is tailored to speciﬁc
patient populations and individual patients. This would
enable effective, efﬁcient triaging of patients into treat-
ment categories ranging from continued risk factor con-
trol to coronary arterial revascularization.
CONCLUSIONS
Despite major advancements in coronary artery im-
aging and identiﬁcation of atherosclerotic lesion
morphology associated with rupture, there is no
conclusive evidence that individual plaque assess-
ment better predicts acute coronary event risk
than established risk factors, such as the extent
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853and severity of coronary artery disease. Pathology
and clinical studies consistently demonstrate that
atherosclerotic plaques rupture without clinical
symptoms much more frequently than is widely
acknowledged, challenging the notion of a close
association between plaque rupture and clinical
events. Conversely, the atherosclerotic disease
burden is a consistent, strong predictor of adverse
cardiovascular events and deserves greater attention.
Current data suggest that rather than focusing onindividual coronary arterial lesions, we need a
comprehensive, integrative approach for identifying
and managing patients at risk of adverse cardiovas-
cular events.
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